The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one master protocol ensures different candidates are evaluated in the same consistent manor and opening up new trials for new candidates is more efficient. Inclusion of new candidates will be based on pre-clinical data, evidence in the clinical setting and GMP capabilities.
AGILE is a multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II Bayesian randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19. This study allows for the assessment of many candidates at different doses, with the ability to add candidates as they are identified or drop them as their evaluation is completed. Promising candidates will move to an external trial for further evaluation in the phase II/III setting. Each candidate will be evaluated in its own trial, randomising between candidate and control with 2:1 allocation in favour of the candidate. Each dose will be assessed for safety sequentially in cohorts of 6 patients. Once a phase II dose has been identified we will assess efficacy by seamlessly expanding into a larger cohort. AGILE is completely flexible in that the core design in the master protocol (as has been explained above) can be adapted for each candidate based on prior knowledge of the candidate - i.e. population, primary endpoint and sample size can be amended. This will be detailed in each candidate-specific trial protocol of the master protocol. Candidate-Specific Trial 2 (CST-2): Open-label 2:1 randomised controlled phase I of EIDD-2801 versus standard of care followed by a 1:1 blinded controlled parallel group Phase II trial of EIDD-2801 versus placebo. A phase I will be carried out to confirm the optimal dose in this group. Following a safety review, EIDD-2801 will be tested for efficacy in a blinded placebo controlled randomised phase II trial. Candidate-Specific Trial 3 (CST-3A): Multicentre, Adaptive, Phase I trial to Determine the optimal dose, Safety and Efficacy of Nitazoxanide for the Treatment of COVID-19 Candidate-Specific Trial 3 (CST-3B): A Randomized, Multicentre, Seamless, Adaptive, Phase I/II trial to Determine the optimal dose, Safety and Efficacy of Nitazoxanide for the Treatment of COVID-19 Candidate-Specific Trial 5 (CST-5): Randomized, Multicentre, Seamless, Adaptive, Phase I/II Platform Study to Determine the Phase II dose of VIR-7832, and Evaluate the Safety and Efficacy of VIR-7831 and VIR-7832 for the Treatment of COVID-19 Candidate-Specific Trial 6 (CST-6): A Randomized, Multicentre, Seamless, Adaptive, Phase I/II Platform Study to Determine the Phase II dose and to Evaluate the Safety and Efficacy of intravenous Favipiravir for the Treatment of COVID-19 Candidate-Specific Trial 8 (CST-8): A Randomised, Multicentre, Seamless, Adaptive, Phase I Platform Study to Determine the recommended Phase II dose and Evaluate the Safety and Efficacy of antiviral combination of Molnupiravir and Paxlovid® for the Treatment of COVID-19 Candidate-Specific Trial 9 (CST-9a): A multicentre, adaptive Phase II Platform trial to evaluate the safety, efficacy and virological response of ALG-097558 as monotherapy and in combination with Remdesivir in high-risk population for the treatment of COVID-19 disease. Candidate-Specific Trial 9 (CST-9b): A Multicentre, Adaptive Phase II Randomised Double-Blind Placebo Controlled Trial to Evaluate the Safety, Efficacy and Virological response of ALG-097558 for the Treatment of COVID-19 disease.
CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST. Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.
CST-2 Phase II: Placebo will be administered orally, twice daily (BID) for 10 doses (5 or 6 days).
CST3A \& CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur. Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.
Desmond Tutu Health Foundation
Cape Town, South Africa
COMPLETEDEzintsha
Johannesburg, South Africa
COMPLETEDLiverpool University Hospitals NHS Foundation Trust
Liverpool, United Kingdom
Master Protocol: Dose-finding/Phase I
Determination of a dose(s) for efficacy evaluation. Dose limiting toxicities (Safety and Tolerability of drug under study - CTCAE v5 Grade ≥3 adverse events)
Time frame: 29 days from randomisation
Master Protocol: Efficacy evaluation/Phase II - Severe patients (Group A)
Determination of activity and safety. In severe patients (Group A): time to clinical improvement. Improvement will be determined according to the WHO Clinical Progression Scale; improvement is defined as a minimum 2-step change from randomisation in the scale up to day 29 post-randomisation.
Time frame: 29 days from randomisation
Master Protocol: Efficacy evaluation/Phase II - Mild to moderate patients (Group B)
Determination of activity and safety. In mild to moderate patients (Group B): pharmacodynamics of drug under study, defined as time to negative viral titres in nose and/or throat swab, measured up to 15 days post-randomisation.
Time frame: 15 days from randomisation
CST-2 Phase I: To determine the safety and tolerability of multiple ascending doses of EIDD-2801 to recommend dose for phase II.
Dose limiting toxicity (DLT) using CTCAE version 5 (grades 3 and above) over 7 days. CTCAE grading related to platelets and/or lymphocytes
Time frame: 7 days from randomisation
CST-2 Phase II: To determine the ability of EIDD-2801 to reduce serious complications of COVID-19 including hospitalization, reduction in SAO2<92%, or death.
Progression of disease (SpO2\<92% based on at least 2 consecutive recordings on the same day) or hospitalization or death up to day 29
Time frame: 29 days from randomisation
CST6 Phase I: To determine the safety and tolerability of multiple doses of IV Favipiravir in patients with COVID-19
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
600
CST-5: Phase I, Single doses of VIR-7832 will be administered by intravenous (IV) infusion over 1 hour. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated, with escalation guided by emerging safety data and decision by the SRC. Phase II: As per Phase I, with the dose determined by the recommended phase II dose.
CST-5 Phase II: A 500 mg dose of VIR-7831 will also be given by IV infusion over 1 hour.
CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour
CST-6: Multiple doses of IV Favipiravir will be administered by intravenous (IV) infusion over 1 hour. Dosing regimen will be every 12 hours for 7 days duration. The starting dose will be 600mg (BID), and dose escalations to 1200mg (BID), 1800mg (BID) and 2400mg (BID) are anticipated as well as a de-escalation dose of 300mg (BID) if necessary, with de-escalation and escalation guided by emerging safety data and decision by the Safety Review Committee (SRC).
Molnupiravir 800mg Twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required.
Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days. The dose of Paxlovid® will be fixed for all cohorts.
ALG-097558 600 mg Twice a day (BD) for 5 days
ALG-097558 600 mg Twice a day (BD) for 5 days Remdesivir will be administered once daily by intravenous infusion over 30 to 120 minutes. 200 mg will be given on day 1 and 100 mg on day 2 and day 3.
NHS standard of care as per COVID-19 treatment guidelines
twice daily (Q12H) oral dose of ALG-097558
twice daily (Q12H) oral dose
Kings College Hospital NHS Foundation Trust
London, United Kingdom
ACTIVE_NOT_RECRUITINGManchester University NHS Foundation Trust
Manchester, United Kingdom
ACTIVE_NOT_RECRUITINGUniversity Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
ACTIVE_NOT_RECRUITINGAdverse events and serious adverse events
Time frame: 29 days from randomisation
CST6 Phase I: To determine the maximum safe dose of IV Favipiravir for efficacy evaluation in phase II
Dose limiting toxicities (Safety and Tolerability of IV Favipiravir- CTCAE v5 Grade ≥3 adverse events)
Time frame: 8 days from randomisation
CST-8 Phase I: Dose Limiting Toxicities up to and including Day 11
Dose limiting toxicities (Safety and Tolerability of molnupiravir and Paxlovid® combination - CTCAE v5 Grade ≥3 adverse events) up to and including Day 11
Time frame: 11 days from randomisation
CST-9a: Dose limiting toxicities up to and including Day 11
Dose limiting toxicities (Safety and Tolerability of ALG-097558 and ALG-097558 plus remdesivir combination - CTCAE v5 Grade ≥3 adverse events) up to and including Day 11
Time frame: 11 days from randomisation
CST-9a: to determine the safety and tolerability of ALG-097558 and ALG-097558 plus remdesivir combination
Adverse events, serious adverse events, physical findings, vital signs, ECG and laboratory parameters
Time frame: 11 days from randomisation
CST-9a: Change in viral titre overtime following administration of ALG-097558 alone and in combination with RDV versus Standard of Care (SoC)
Qualitative (and quantitative when possible) PCR for SARS-CoV-2 by nose and throat swab
Time frame: 11 days from randomisation
CST-9a: Sustained symptom resolution
Symptom resolution evaluated through questionnaires
Time frame: 29 days from randomisation
CST-9b
AEs, SAEs
Time frame: 11 Days from randomisation
CST-9b
Dose Limiting Toxicity (DLT) using CTCAE version 5 (grades 3 and above) up to and including Day 11
Time frame: 11 days from randomisation
CST-9b
Qualitative (and quantitative when possible) PCR for SARS-CoV-2 by nose and throat swab
Time frame: 11 days from randomisation
Master Protocol: Safety assessed by rate of adverse events
Adverse event rate according to CTCAE v5
Time frame: Up to 29 days from randomisation
Master Protocol: To evaluate clinical improvement
Proportion of patients with clinical improvement (as defined above) at day 8, 15 and day 29.
Time frame: From randomisation to day 29
Master Protocol: To evaluate clinical improvement using WHO clinical progression scale
Change at day 8 and 15 from randomisation in the WHO Clinical Progression Scale
Time frame: From randomisation to day 15
Master Protocol: To evaluate clinical improvement using WHO clinical progression scale
Time to a one point change on the WHO Clinical Progression Scale
Time frame: From randomisation to day 29
Master Protocol: To evaluate clinical improvement using SpO2/FiO2
The ratio of the oxygen saturation to fractional inspired oxygen concentration (SpO2/FiO2)
Time frame: From randomisation to day 29
Master Protocol: To evaluate discharge
Proportion of patient discharged at days 8, 15 and 29
Time frame: From randomisation to day 29
Master Protocol: To evaluate admission to ICU
Admission rate to ICU
Time frame: From randomisation to day 29
Master Protocol: To evaluate safety further (WCC)
White cell count on day 1, 3, 5, 8, 11 (while hospitalised); and Day 15 and 29
Time frame: From randomisation to day 29
Master Protocol: To evaluate safety further (Hg)
Haemoglobin on day 1, 3, 5, 8, 11 (while hospitalised); and Day 15 and 29
Time frame: From randomisation to day 29
Master Protocol: To evaluate safety further (platelets)
Platelets on day 1, 3, 5, 8, 11 (while hospitalised); and Day 15 and 29
Time frame: From randomisation to day 29
Master Protocol: To evaluate safety further (creatinine)
Creatinine on day 1, 3, 5, 8, 11 (while hospitalised); and Day 15 and 29
Time frame: From randomisation to day 29
Master Protocol: To evaluate safety further (ALT)
ALT on day 1, 3, 5, 8, 11 (while hospitalised); and Day 15 and 29
Time frame: From randomisation to day 29
Master Protocol: To evaluate overall mortality
Mortality at Days 8, 15 and 29. Time to death from randomisation
Time frame: From randomisation to day 29
Master Protocol: To evaluate the number of oxygen-free days
Duration (days) of oxygen use and oxygen-free days
Time frame: From randomisation to day 29
Master Protocol: To evaluate ventilator-free days
Duration (days) of mechanical ventilation and mechanical ventilation-free days
Time frame: From randomisation to day 29
Master Protocol: To evaluate incidence of new mechanical ventilation use
Incidence of new mechanical ventilation use
Time frame: From randomisation to day 29
Master Protocol: To evaluate National Early Warning Score (NEWS)2/qSOFA
NEWS2/qSOFA assessed daily while hospitalised
Time frame: From randomisation to day 29
Master Protocol: To evaluate translational outcomes (Viral Load)
Change in viral load over time
Time frame: From randomisation to day 29
Master Protocol: To evaluate translational outcomes (Baseline SARS-COV-2)
Change in viral load over time
Time frame: From randomisation to day 29
CST-2 Additional: Pharmacokinetic Objective: To define PK of EIDD-2801 and EIDD-1931 in plasma following multiple doses administered to patients with COVID-19.
Concentrations of EIDD-2801 and -1931 in plasma
Time frame: Samples collected on Day 1 and Day 5 post-randomisation
CST-2 Additional: Virologic Objective: To assess the difference in viral clearance (time to negative PCR) between EIDD-2801 and control.
Qualitative (and quantitative when possible) PCR for SARS-CoV-2 by nasal swab.
Time frame: Swabs taken on Day 1 (day of randomisation), 3, 5, 8, 11, 15, 22 and 29
CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (FLU-PRO)
Patient Reported Outcome Measures (FLU-PRO).
Time frame: From randomisation to Day 29
CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (WHO Scale).
WHO Progression Scale at day 15 and 29
Time frame: From randomisation to Day 29
CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (NEWS2)
NEWS2 (National Early Warning Score2) assessed during study clinic visit on days 15 and 29.
Time frame: From randomisation to Day 29
CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (mortality)
Mortality at Days 15 and 29
Time frame: From randomisation to Day 29
CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (death)
Time from randomisation to death
Time frame: From randomisation to Day 29
CST-6 Additional: To characterise the pharmacokinetics (PK) of multiple doses of IV Favipiravir
Plasma PK parameters of IV Favipiravir
Time frame: From randomisation to Day 8
CST-6 Additional: To investigate the ability of IV Favipiravir to reduce the duration of signs and symptoms of COVID-19 in-patients
WHO Progression Scale (WHO, 2020)
Time frame: Randomisation to Day 15 and Day 29
CST-6 Additional: To investigate the effect of IV Favipiravir on SARS-CoV-2 viral load
Viral load change from baseline over time
Time frame: From randomisation to Day 29
CST-8: Assess feasibility for late phase study by reviewing any recorded AEs and SAEs
Review of any adverse events
Time frame: From randomisation to Day 29
CST-8: Assess feasibility for late phase study by reviewing hospitalisation or death up to Day 29
Death and hospitalisation up to Day 29
Time frame: From randomisation to Day 29
CST-8: Measure concentrations of IMP re evidence of virological efficacy
PK concentrations of both IMPs and their circulating metabolites in plasma.
Time frame: From randomisation to Day 11
CST-8: Measure PK of each drug within the combination
PK concentrations of both IMPs and their circulating metabolites in plasma.
Time frame: From randomisation to Day 11
CST8: Review evidence of virological efficacy via viral elimination slopes
Qualitative (and quantitative when possible) PCR for SARS-CoV-2 by nose and throat swab
Time frame: From baseline to Day 11
CST8: Vital signs (Heart Rate) at Screening, Baseline/Day 1, Day 3, Day 5 and Day 11
Vital sign measure 1 heart rate (beats/min) - to be part of aggregated review of pt vitals to assess safety and tolerability.
Time frame: From randomisation to Day 11
CST-8: Vital signs (Blood Pressure) at Screening, Baseline/Day 1, Day 3, Day 5 and Day 11
Vital sign measure 2 Blood Pressure (mmHG) - to be part of aggregated review of pt vitals to assess safety and tolerability.
Time frame: From randomisation to Day 11
CST-8: Vital signs (Respiratory Rate) at Screening, Baseline/Day 1, Day 3, Day 5 and Day 11
Vital sign measure 3 respiratory rate (breaths/min) - to be part of aggregated review of pt vitals to assess safety and tolerability.
Time frame: From randomisation to Day 11
CST-8: Vital signs (Temperature) at Screening, Baseline/Day 1, Day 3, Day 5 and Day 11
Vital sign measure 4 temperature (degrees c) - to be part of aggregated review of pt vitals to assess safety and tolerability.
Time frame: From randomisation to Day 11
CST-8: Vital signs (Oxygen Saturation) at Screening, Baseline/Day 1, Day 3, Day 5 and Day 11
Vital sign measure 5 oxygen saturation (FiO2 as %) - to be part of aggregated review of pt vitals to assess safety and tolerability.
Time frame: From randomisation to Day 11
CST-9a: Measure PK of ALG-097558 plus remdesivir in plasma
PK concentrations of ALG-097558 and remdesivir and metabolites in plasma
Time frame: Day 1 to day 3
CST-9a: establish disease progression endpoints including visits to emergency department, hospitalisations, all- cause mortality
Death, hospitalisation, and hospital/GP visits
Time frame: From randomisation to Day 29
CST-9a: incidence of rebound SARS-CoV-2 infection
Proportion of participants with clinical and/or virologic rebound
Time frame: From randomisation to Day 29
CST-9a: Symptom improvement in subgroup of severely immunosuppressed participants or with high baseline viral titre
Symptom improvement evaluated through questionnaires
Time frame: From randomisation to Day 29
CST-9: Viral dynamics in subgroup of severely immunosuppressed participants or with high baseline viral titre
Viral dynamics in subgroup of severely immunosuppressed participants or with high baseline viral titre
Time frame: From randomisation to Day 29
CST-9b
Plasma PK, concentrations ALG-097558 and its metabolites
Time frame: 11 days from randomisation
CST-9b
Death, hospitalisation, and hospital/GP visits up to Day 29
Time frame: 29 Days from randomisation
CST-9b
Proportion of participants with clinical and/or virologic rebound
Time frame: 11 Days from randomisation
CST-9b
Viral dynamics in subgroup of participants with high baseline viral titre (defined as Ct value of \<22)
Time frame: 11 Days from randomisation
CST-9b
Viral dynamics in subgroup of participants randomized within 3 days of symptom onset
Time frame: 11 Days from randomisation
CST-9b
Time to sustained symptom resolution (evaluated through questionnaires as a participant-reported outcome)
Time frame: 11 Days from randomisation